KEVEYIS[®](dichlorphenamide) PRESCRIPTION START FORM

FAX completed form to 1-312-276-4846 phone 1-844-538-3947



PATIENT INFORMATION				
FIRST NAME:	LAST NAME:	MIDDLE INITIAL:	SEX: 🗌 MALE 📋 FEMALE	
DOB (MM/DD/YYYY):	EMAIL ADDRESS:	HEIGHT:	WEIGHT: LB KG	
ADDRESS:	CITY	/STATE/ZIP CODE:		
HOME PHONE:	CEL	L PHONE:		
CAREGIVER NAME (IF APPLICABLE):	PHC	DNE NUMBER:		
	PRESCRIPTION DRUG I	NSURANCE INFORMATION		
PLEASE SEND A COPY (FRONT AND B PRIMARY INSURANCE:		N, MEDICAL, AND SECONDARY INSURA X PCN#: RX ID#:	NCE CARDS. RX GROUP#:	
CARDHOLDER NAME:	RELATIO	NSHIP TO CARDHOLDER: 🗌 SELF 📋 SF	POUSE CHILD OTHER	
EMPLOYER:		RX ID#:		
SECONDARY INSURANCE:	RX BIN#: R	X PCN#:	RX GROUP#:	
CARDHOLDER NAME:	RELATIO	NSHIP TO CARDHOLDER: 🗌 SELF 🗌 SF	POUSE CHILD OTHER	
	CLINICAL I	NFORMATION		
PRIMARY DIAGNOSIS:	ICD-10 CODE:	G72.3 G71.19 OTHER (SPECIFY):		
TYPE OF PRIMARY PERIODIC PARALYS	IS: HYPERKALEMIC HYPOKALEMI	C 🗌 PARAMYOTONIA CONGENITA 🗌 C	THER (SPECIFY):	
ALLERGIES:			NO KNOWN DRUG ALLERGIES	
COMORBIDITIES:				
	PRESCRIPTIO	N INFORMATION		
PRESCRIPTION: KEVEYIS (dichlorphen	amide) 50 mg tablets			
DISPENSE: 30-DAY SUPPLY RE	FILLS			
	DIRECTIC	NS FOR USE		
PLEASE CHECK ONE OF THE FOLLOW TITRATION/OTHER DOSING INSTRUCT		CE DAILY TAKE 1 TABLET BY MOUTH	TWICE DAILY	
Initial dose: 50 mg once or twice daily. Titrate dose is 200 mg daily.	dose lower or higher, based on individual respo	onse, at weekly intervals (or sooner in case of adv	rerse reaction). The maximum recommended	
or other patient information relating to dispensing KEVEYIS) to use and disclo and submit prior authorization reques	o KEVEYIS therapy to agents of Xeris Pha se as necessary for prior authorization pr ts, appeal requests, and other administra one calls, mail, email, or any other form of	tive tasks on behalf of the prescriber and	uding, but not limited to, pharmacies on. I authorize CloudTop Health to prepare	
SICN PHYSICIAN'S SIGNATURE (CH	DOSE ONE)			
DISPENSE AS WRITTEN*	DATE	SUBSTITUTION ALLOWED	DATE	
ANY SPECIAL INSTRUCTIONS:				
	/ necessary" or other language to be ha	ndwritten by the prescriber if he/she has	s made this determination in his/her	
	comply with his/her state-specific prescrip e-specific requirements could result in ou	tion requirements such as e-prescribing, s treach to the prescriber.	state-specific prescription form, fax	
confidential. It may also contain privilege and Accountability Act (HIPAA). If you are (other than to the intended recipient) or	ed, confidential information that is exemp e not the intended recipient, please note t	t from disclosure under applicable laws, ir hat you are strictly prohibited from dissen his communication in error, please notify 1		
	PRESCRIBE			
FIRST NAME:	LAST NAME:	NPI#:	DEA#:	

FIRST NAME:	LAST NAME:	NPI#:	DEA#:	
OFFICE ADDRESS:		CITY/STATE/ZIP CODE:		
SHIP TO: PATIENT OFFICE	PHONE:	FAX:		
PA CONTACT NAME:	OFFICE EMAIL ADDRES	SS:	OFFICE PHONE:	

Your patient will be contacted by PANTHERx Rare Pharmacy to arrange for delivery of KEVEYIS.

KEVEYIS®, Xeris Pharmaceuticals®, Xeris CareConnection™, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc. PANTHERX Rare Pharmacy is a service mark of PANTHERX Rare, LLC. Copyright © 2023-2025 Xeris Pharmaceuticals, Inc. All rights reserved. US-KEV-22-00028v5 4/2025

KEVEYIS[®](dichlorphenamide) PRESCRIPTION START FORM

FAX completed form to 1-312-276-4846 phone 1-844-538-3947



XERIS CARECONNECTION™ PATIENT SUPPORT SERVICES

By signing this Authorization, I understand I am giving Xeris Pharmaceuticals[®], its affiliates, and business partners permission to use the personal information provided in this registration form to contact me by the following methods, but not limited to: mail, email, telephone call, or text, about disease and product information, disease or product-related events, support services, market research, and to share other promotional information. By submitting this form, I consent to these uses and agree to the Xeris Pharmaceuticals privacy statement located at <u>xerispharma.com/privacy-policy</u>. I understand I can opt out by clicking on the unsubscribe link in future communications or by sending a letter with my full contact information (eg, name, address, email address, phone number, etc) to Xeris CareConnection Patient Support Services, 1375 West Fulton Street, Suite 1300, Chicago, IL 60607.

AUTHORIZATION AND RELEASE OF HEALTH INFORMATION

By signing this Authorization, I authorize each of my physicians, pharmacies, other healthcare providers, and each of my health insurers, to use and disclose health information related to my taking KEVEYIS® that identifies me personally, including my name, address, and telephone number(s) and information about my insurance, prescriptions, medical condition and health (my "Information") to Xeris Pharmaceuticals® (the manufacturer of KEVEYIS), its Xeris CareConnection™ Patient Support Services, and their respective agents, contractors, and third-party vendors, including providers of alternate sources of funding for prescription drug costs (collectively, "the Program") so that the Program may: (I) help to verify, assist with, and coordinate insurance coverage or otherwise obtain payment for my treatment with KEVEYIS; (2) coordinate my receipt of, and payment for, KEVEYIS; (3) conduct analytics to gain insight into and support the effectiveness of the Program; and (4) provide me with adherence reminders and support for KEVEYIS including email or text.

I understand that once my Information has been disclosed to the Program, state and federal privacy laws may no longer protect the Information and that it may be subject to further disclosure by the Program. I also understand that the Program intends to use and disclose my Information only for the purposes described in this Authorization and that results of the analytics will only be shared outside of the Program after being anonymized. I understand that my pharmacy, health insurance company and healthcare providers may receive payment from Xeris Pharmaceuticals in exchange for disclosing my Information to the Program and/or for providing me with therapy support services. I understand that I do not have to sign this Authorization and that my treatment, payment for treatment, insurance enrollment, or eligibility for insurance benefits will not be affected if I do not sign it. I also understand, however, that if I do not sign this Authorization, the Program cannot provide me with assistance.

This Authorization will remain in effect for five (5) years, unless I cancel my enrollment before then. I understand that I may cancel (revoke) the Authorization at any time by sending a written notice of cancellation to: Xeris CareConnection Patient Support Services, 1375 W Fulton Street, Suite 1300, Chicago, IL 60607. I understand that if I do cancel this Authorization, the cancellation will be effective for each of my healthcare providers and health plans/insurers upon receipt by each such entity, respectively, but will not affect any information already disclosed. I understand that I am entitled to a copy of this Authorization after signing on the previous page.

PATIENT INFORMATION			
FIRST NAME:	LAST NAME:	DOB (MM/DD/YYYY):	
CHECK THE BOXES B	BELOW TO CONFIRM YOU HAVE READ AND AGREE TO	THE FOLLOWING SERVICES AND AUTHORIZATIONS:	
	RELEASE OF HEALTH INFORMATION ATIENT SUPPORT SERVICES		
PATIENT NAME:		RELATIONSHIP TO PATIENT:	
SICN PATIENT/AUTHORIZ	ZED PARTY SIGNATURE:	DATE:	

QUESTIONNAIRE

PRESCRIBER INFORMATION			
FIRST NAME:	LAST NAME:	NPI#:	
ADDRESS:		CITY/STATE/ZIP CODE:	
PATIENT INFORMATION			
FIRST NAME:	LAST NAME:	DOB:	
ADDRESS:		CITY/STATE/ZIP CODE:	

PRIOR AUTHORIZATION REQUEST

The patient's insurance requires prior authorization for this prescription. If you would like us to submit and follow up on the request, send a copy of the medication form, chart notes, labs and radiology reports along with this form.

CLINICAL INFORMATION					
What is the diagnosis?	Hyperkalemic periodic para Primary periodic paralysis va				
Diagnosis confirmed by: (please attac Family History Documented Clinica					
Has the patient been admitted to a h	ospital due to their PPP?		YES	NO	
Has the provider confirmed the patier hypersensitivity to sulfonamides, seve			nsufficienc YES	ey, No	
Have nonpharmacologic intervention	s been tried (e.g. diet, refraining fro	m vigorous exercise)?	YES	NO	
Has acetazolamide been tried and fail If yes, indicate reason for failure:		ntolerance or hypersensitivity	YES y Contra	NO aindication	
Has generic dichlorphenamide been t If yes, indicate reason for failure:		ntolerance or hypersensitivity	YES y Contra	NO aindication	
In the prescriber's opinion, is KEVEYIS Alternatives would not be as effective Alternatives would likely have adverse	for treating the patient's condition.	patient?			
ALL INFORMATION IS TRUE AND ACCURATE T * Prescriber Signature:	TO THE BEST OF MY KNOWLEDGE.	Title:			